| 000 | 01531 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518093133.0 | ||
| 264 | 0 | _c20210105 | |
| 008 | 202101s 0 0 eng d | ||
| 022 | _a1873-1449 | ||
| 024 | 7 |
_a10.1016/j.brachy.2020.01.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStone, Nelson N | |
| 245 | 0 | 0 |
_aLong-term biochemical control and cause-specific survival in men with Gleason grade Group 4 and 5 prostate cancer treated with brachytherapy and external beam irradiation. _h[electronic resource] |
| 260 |
_bBrachytherapy _c |
||
| 300 |
_a275-281 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aBrachytherapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIodine Radioisotopes _xtherapeutic use |
| 650 | 0 | 4 |
_aKallikreins _xblood |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Grading |
| 650 | 0 | 4 |
_aPalladium _xtherapeutic use |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xblood |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xblood |
| 650 | 0 | 4 |
_aRadioisotopes _xtherapeutic use |
| 650 | 0 | 4 | _aRadiotherapy Dosage |
| 650 | 0 | 4 | _aRadiotherapy, Conformal |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aSkouteris, Vassilios | |
| 700 | 1 | _aStock, Richard G | |
| 773 | 0 |
_tBrachytherapy _gvol. 19 _gno. 3 _gp. 275-281 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.brachy.2020.01.008 _zAvailable from publisher's website |
| 999 |
_c30785057 _d30785057 |
||